Multiple Sclerosis Trial, Not Yet Recruiting NCT06228781 Sponsor: Tianjin Medical University General Hospital Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Not Yet Recruiting

NCT06228781
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged between 18 and 60 years old.
  • People who have been diagnosed with multiple sclerosis (MS) involving relapses or worsening, along with lasting disability, as confirmed by a specialist neurologist.
  • People with an EDSS score (a standard measure of MS-related disability) between 3 and 6, including those scoring exactly 3 or 6.
  • People whose MS has significantly affected either their balance and coordination (cerebellar function) or their muscle strength and movement (pyramidal function), as measured by specific parts of the EDSS scale.
  • People whose MS is currently showing signs of active disease.
  • People who have previously received certain chemotherapy-type medicines (such as mitoxantrone or cyclophosphamide) and whose bone marrow tests show normal results before the trial begins.
  • People with no signs of liver inflammation or scarring.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who show signs of a bone marrow disorder (myelodysplasia) or certain blood cell problems not caused by an autoimmune condition.
  • People who have received chemotherapy-type medicines within one month before enrolling in the trial.
  • People who have any active or ongoing infection, such as herpes, chickenpox-related viruses, HIV, hepatitis, syphilis, or similar infections.
  • People who have received chemotherapy-type medicines within one month before enrolling in the trial (confirm with trial site, as this criterion appears twice in the source).
  • People who currently have, or have had, a cancerous tumour within the last five years.
  • People who have significant problems with their heart, kidneys, lungs, liver, or other major organs.
  • People whose life expectancy is seriously limited by another medical condition.
  • People who are pregnant or at risk of becoming pregnant.
  • People who are unable to provide written consent to participate, in line with research ethics requirements.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Qiang Liu, M.D.,Ph.D, Tianjin Medical University General Hospital

Phone: +86 15022439149

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Tianjin Medical University General Hospital
Registry
ClinicalTrials.gov
Start date
1 December 2026
Est. completion
1 January 2029

Primary endpoints

3 year MS activity free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov